Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man; Awards $150 Million in Punitive Damages

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug. “This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. […]

July 24, 2017

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug.

“This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears it,” said MDL co-lead counsel Chris Seeger.  Mr. Mitchell is one of more than 4,000 plaintiffs who have sued AbbVie Inc. in the federal multidistrict litigation, In re: Testosterone Replacement Therapy Products Liability Litigation, case number 1:14-cv-01748, before Judge Matthew Kennelly in the U.S. District Court for the Northern District of Illinois. Mr. Mitchell claimed that AbbVie fraudulently misled doctors and patients about the drug’s benefits and risks—in particular, cardiovascular risks—when marketing the drug. The jury deliberated for 4 hours before reaching its verdict.  Partner Dave Buchanan, a member of the Mitchell trial team, commented, “For years before Jesse took AndroGel, AbbVie promoted unproven benefits and falsely assured doctors and patients about the safety of the drug.  The consequences of those acts are serious and real—facts that weren’t lost on this jury.”

Mr. Mitchell was represented by Troy Rafferty of Levin Papantonio, lead, David Buchanan of Seeger WeissBill Robins of Robins Cloud, Stephanie O’Connor of Douglas & London, and David Diamond of Goldberg & Osborne. The case is Mitchell et al. v. AbbVie Inc. et al., case number 1:14-cv-09178.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

June 12, 2025
Seeger Weiss and Partners Recognized in the Chambers 2025 USA Guide

Seeger Weiss is proud to announce that the firm—alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya—has been recognized in the newly released Chambers 2025 USA Guide. This marks the fifth consecutive year that Seeger Weiss has been recognized by Chambers USA. For over three decades, Chambers has been a trusted authority in […]

Read More
June 10, 2025
Ten Seeger Weiss Attorneys Named to Lawdragon’s 2025 500 Leading Plaintiff Financial Lawyers List

We are proud to announce that ten Seeger Weiss attorneys have been selected to Lawdragon’s 2025 Leading Plaintiff Financial Lawyers guide list, which honors attorneys who represent plaintiffs in complex financial litigation. Congratulations to Parvin Aminolroaya, Christopher Ayers, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, Christopher Seeger, and Stephen […]

Read More
May 28, 2025
Seeger Weiss Establishes Fund at Bolch Judicial Institute to Defend the Judiciary and Honor Daniel Anderl

Seeger Weiss LLP, led by founding partner Christopher A. Seeger, has made a $500,000 donation to the Bolch Judicial Institute at Duke Law School to establish The Seeger Weiss/Daniel Anderl Memorial Fund, which will provide long-term, flexible funding for the Institute to support two critical areas of the legal system: defending judicial independence and advancing […]

Read More